China's Henlius H1 revenue jumps on drug sales, license income

Shanghai Henlius Biotech

21/08/2026 12:36

Overview
China biopharma firm's interim revenue rose 27% yr/yr, driven by drug sales and licensing
Company expanded global footprint with new drug approvals and licensing agreements
R&D expenditure increased as company accelerated innovation and clinical pipeline expansion

Outlook
Company aims to expand global commercial footprint through licensing and new collaborations
Henlius plans to deepen internationalisation strategy in EU and other regions for key cancer indications
Company continues to expand R&D pipeline and pursue new clinical trial approvals

Result Drivers
DRUG SALES & LICENSING - Co said revenue growth was mainly driven by sales of commercialized drugs and license income
OVERSEAS EXPANSION - Co said increased sales and royalty income from overseas products contributed to international profitability
R&D INVESTMENT - Co said higher R&D expenditure was driven by accelerated investment in innovative research and clinical pipeline expansion

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 3.59 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Shanghai Henlius Biotech, Inc. is HK$101.35, about 47.7% above its August 21 closing price of HK$68.60
The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 41 three months ago

Reuters Recommended Reads
Aug 21 - Biotech firm Antengene's H1 revenue jumps on licensing deals
Aug 19 - China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up
Aug 20 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)